RABBIT is financially supported by a joint grant from all companies that provide biologic DMARDs for therapy of rheumatoid arthritis. The sponsorship is unconditional; therefore, solely the principle investigators and the scientific advisory board are responsible for data acquisition and analysis as well as for publication of results; the drug manufacturers have no influence over this.
AbbVie Deutschland GmbH & Co. KG |
Amgen GmbH |
Biocon Biologics Germany GmbH |
Bristol-Myers Squibb GmbH & Co. KGaA |
Celltrion Inc. |
Fresenius Kabi SwissBioSim GmbH |
Hexal AG |
Lilly Deutschland GmbH |
MSD Sharp & Dohme GmbH |
MYLAN S.A.S. |
Pfizer Pharma GmbH |
Roche Pharma AG |
Samsung Bioepis Co., Ltd. |
Sanofi-Aventis Deutschland GmbH |
Swedish Orphan Biovitrum (vorher Amgen) (bis 2012) |
UCB Biosciences GmbH |